WhatsApp

Which HIPEC Drug Combination Works Better for Pseudomyxoma Peritonei?

You are here >> Home > Latest Updates > GI & HPB > HIPEC > Which HIPEC…

Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma DOI- 10.108002656736.2025.2467296

Pseudomyxoma peritonei (PMP) is a rare cancer that usually starts in the appendix and spreads inside the belly. It leads to a jelly-like buildup in the abdomen and can make people very sick. Surgery is the main treatment, and it is often followed by a special heated chemotherapy treatment in the belly, called HIPEC.

This study looked at two different chemotherapy mixes used in HIPEC after surgery. One mix had cisplatin and docetaxel (CD), and the other had cisplatin and mitomycin C (CM). Doctors wanted to know which worked better to help people live longer and stay safe during treatment.

Researchers looked back at records from 104 patients treated between 2008 and 2023. Half got the CD treatment and half got the CM treatment. The team made sure both groups were similar so they could compare them fairly.

Patients who got the CD mix lived much longer—more than 13 years on average, compared to just over 5 years for those on the CM mix. Side effects were about the same for both groups, which means the CD mix didn’t cause more harm.

The benefit of the CD mix was even greater for people with more advanced disease, higher tumor markers, or lower body weight. This means doctors may be able to better match the treatment to each patient’s condition.

This study shows that using cisplatin with docetaxel in HIPEC may be a better option for people with PMP. It offers new hope for patients and could help doctors improve outcomes in this rare and difficult cancer.

Rate this post
Robotic Cancer Surgery
Best robotic cancer surgery in Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.